RECRUITING

Autologous Volar Fibroblast Injection Into the Stump Site of Amputees

Description

This study is a clinical trial testing the safety and efficacy of volar fibroblast (skin cells from the palm or sole) injections for thickening the epidermal (skin) layer at the stump site in people with below the knee amputations. The study will enroll adults seen at Johns Hopkins.

Study Overview

Study Details

Study overview

This study is a clinical trial testing the safety and efficacy of volar fibroblast (skin cells from the palm or sole) injections for thickening the epidermal (skin) layer at the stump site in people with below the knee amputations. The study will enroll adults seen at Johns Hopkins.

Autologous Volar Fibroblast Injection Into the Stump Site of Amputees

Autologous Volar Fibroblast Injection Into the Stump Site of Amputees

Condition
Amputation
Intervention / Treatment

-

Contacts and Locations

Baltimore

Department of Dermatology at Johns Hopkins University, Baltimore, Maryland, United States, 21287

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * A skin erosion deeper than the skin dermis.
  • * Having received any investigational drug within 30 days prior to study entry
  • * An allergy history to any study materials including local anesthetic, dimethyl sulfoxide, human albumin, or bovine constituents, hetastarch, or EMLA (lidocaine 2.5% and prilocaine 2.5%).
  • * Pregnant, lactating, or trying to become pregnant
  • * A history of keloid formation
  • * Having a significant medical history that the investigator feels is not safe for study participation (for example, some forms of autoimmune conditions, metastatic cancer, infectious diseases such as HIV, HTLV I/II, Hepatitis B, Hepatitis C). Biopsies taken from individuals with infections that are not allowed to enter the cell therapy core will make it such that these individuals cannot participate.
  • * Specifically we will exclude those with autoimmune diseases affecting the skin such as lupus.
  • * Presence of necrotic ischemic tissue on any stump ulcers, and/or capillary refill on stump skin of greater than 3 seconds
  • * Active infection of the residual limb.
  • * Active smoker during the study
  • * We will also exclude those who are on chronic immunosuppressive therapies such as oral steroids, but also those on chronic topical steroids in the area of investigation.
  • * Recent amputee who has not yet been approved to use a prosthetic.
  • * Use of a prosthetic for less than 3 months.
  • * Amputees with neuromas of the terminal limb within the last 3 months.
  • * Known bleeding disorder.
  • * For those receiving Bellafill/collagen skin test: history of serious allergy, such as anaphylaxis.
  • * For whole stump injections: Have a history of congenital or idiopathic methemoglobinemia, glucose-6-phosphate deficiencies, or use of medications associated with drug-induced methemoglobinemia. (specifically: Sulfonamides, Acetaminophen, Acetanilid, Aniline dyes, Benzocaine, Chloroquine, Dapsone, Naphthalene, Nitrates and Nitrites, Nitrofurantoin, Nitroglycerin, Nitroprusside, Pamaquine, Para-aminosalicylic acid, Phenacetin, Phenobarbital, Phenytoin, Primaquine, or Quinine.)

Ages Eligible for Study

18 Years to 65 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

Yes

Collaborators and Investigators

Johns Hopkins University,

Luis Garza, MD PhD, PRINCIPAL_INVESTIGATOR, Johns Hopkins University

Study Record Dates

2028-04-01